Patient demographics and MDS disease characteristics
| Demographics/characteristics . | n (%) . |
|---|---|
| Age, y* | |
| < 65 | 8 (18) |
| ≥ 65 | 37 (82) |
| Sex | |
| Male | 33 (73) |
| Female | 12 (27) |
| ECOG performance status | |
| 0 | 20 (44) |
| 1 | 25 (56) |
| Baseline cytogenetics | |
| Normal | 22 (49) |
| Abnormal | 16 (36) |
| Unknown | 7 (16) |
| IPSS classification | |
| Low risk | 14 (31) |
| INT-1 risk | 28 (62) |
| INT-2 risk | 3 (7) |
| High risk | 0 |
| FAB/WHO diagnosis classification | |
| RA† | 9 (20) |
| RARS† | 11 (24) |
| RAEB/RAEB-1† | 3 (7) |
| RAEB-II‡ | 1 (2) |
| RCMD‡ | 8 (18) |
| RCMD-RS‡ | 2 (4) |
| MDS-U‡ | 5 (11) |
| CMML§ | 2 (4) |
| Unknown | 4 (9) |
| Transfusion dependency | |
| RBC transfusion dependent | 27 (60) |
| Platelet transfusion dependent | 5 (11) |
| Cell-lineage cytopenia | |
| Anemia | 35 (78) |
| Neutropenia | 21 (47) |
| Thrombocytopenia | 25 (56) |
| Bilineage cytopenia | 22 (49) |
| Unilineage cytopenia | 16 (36) |
| Trilineage cytopenia | 7 (16) |
| Demographics/characteristics . | n (%) . |
|---|---|
| Age, y* | |
| < 65 | 8 (18) |
| ≥ 65 | 37 (82) |
| Sex | |
| Male | 33 (73) |
| Female | 12 (27) |
| ECOG performance status | |
| 0 | 20 (44) |
| 1 | 25 (56) |
| Baseline cytogenetics | |
| Normal | 22 (49) |
| Abnormal | 16 (36) |
| Unknown | 7 (16) |
| IPSS classification | |
| Low risk | 14 (31) |
| INT-1 risk | 28 (62) |
| INT-2 risk | 3 (7) |
| High risk | 0 |
| FAB/WHO diagnosis classification | |
| RA† | 9 (20) |
| RARS† | 11 (24) |
| RAEB/RAEB-1† | 3 (7) |
| RAEB-II‡ | 1 (2) |
| RCMD‡ | 8 (18) |
| RCMD-RS‡ | 2 (4) |
| MDS-U‡ | 5 (11) |
| CMML§ | 2 (4) |
| Unknown | 4 (9) |
| Transfusion dependency | |
| RBC transfusion dependent | 27 (60) |
| Platelet transfusion dependent | 5 (11) |
| Cell-lineage cytopenia | |
| Anemia | 35 (78) |
| Neutropenia | 21 (47) |
| Thrombocytopenia | 25 (56) |
| Bilineage cytopenia | 22 (49) |
| Unilineage cytopenia | 16 (36) |
| Trilineage cytopenia | 7 (16) |
ECOG indicates Eastern Cooperative Oncology Group; IPSS, International Prognostic Scoring System; WHO, World Health Organization; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenias with multilineage dysplasia; RCMD-RS, refractory cytopenias with multilineage dysplasia with ringed sideroblasts; MDS-U, myelodysplastic syndrome-unclassified; CMML, chronic myelomonocytic leukemia; and RBC, red blood cells.
Age in years, median (range): 71 (53-84).
FAB/WHO.
WHO.
FAB.